Article Per Year (5 Year)
p-Index From 2020 - 2025
2.426
P-Index
This Author published in this journals
All Journal Jurnal Veteriner Jurnal Ilmiah Aplikasi Isotop Radiasi Microbiology Indonesia Media Penelitian dan Pengembangan Kesehatan Health Science Journal of Indonesia Universa Medicina Paediatrica Indonesiana Molecular and Cellular Biomedical Sciences (MCBS) The Indonesian Journal of Infectious Diseases JHECDs: Journal of Health Epidemiology and Communicable Diseases Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Daengku: Journal of Humanities and Social Sciences Innovation Indonesian Journal of Health Science Makara Journal of Science Makara Journal of Technology Jurnal Kefarmasian Indonesia Jurnal Bioteknologi & Biosains Indonesia (JBBI) InaBHS (Indonesian Journal of Biomedicine and Health Science) Jurnal Bioteknologi & Biosains Indonesia
Budiman Bela
Departemen Mikrobiologi Fakultas Kedokteran Universitas Indonesia/KSM Mikrobiologi Klinik RSUPN Dr Cipto Mangunkusumo, Jakarta, Indonesia
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Decision Sciences, Operations Research & Management Dentistry Education Electrical & Electronics Engineering Engineering Environmental Science Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Materials Science & Nanotechnology Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary Other

Published : 27 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 27 Documents
Search

 1   2   3 
SARS-CoV-2 multi-epitope subunit vaccine proof-of-concept derived from the in silico study with protein expression in E. coli BL21 Muhayya, Syarifah Raisha; Agus Ariyanto, Ibnu; Widianingtyas, Silvia; Subiantistha, Tanaya; Bela, Budiman
Pharmaceutical Journal of Indonesia Vol. 9 No. 2 (2024)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2024.009.02.1

Abstract

The protein subunit vaccine is the most considerably developed SARS-Cov-2 vaccine, according to the WHO vaccine tracker in 2023. The acceleration of vaccine development in 2 years of eradicating the COVID-19 pandemic is attainable due to the role of bioinformatics. The objective of this paper is to evaluate strategies for developing multi-epitope SARS-Cov-2 recombinant vaccines with high protein expression in silico. The study was conducted by analyzing SARS-Cov-2 epitopes using immunoinformatics tools provided by IEDB, codon optimization, rare codon analysis, plasmid design, and ribosomal binding site (RBS) analysis were analyzed using RNA structure 6.4, gene cloning by E. coli DH5α and protein expression by E. coli BL21. Each epitope peptide candidate was linked to a flexible linker sequence (GGGGS). GelAnalyzer 19.1 was utilized to determine the protein band of SDS-PAGE. The immunoinformatics study obtained multi-epitope of the recombinant SARS-COV-2 vaccine with a total of 7 epitopes for HLA-I allele candidates and 4 for HLA-II. It is demonstrated that the candidate vaccine protein was successfully cloned in E. coli DH5α and expressed in E. coli BL21.
Respons imun seluler terhadap antigen E2, E6, dan E7 HPV16: Pemanfaatannya pencegahan dan terapi kanker serviks Utami, Mardhah Sastri; Bela, Budiman
Indonesian Journal of Health Science Vol 4 No 5 (2024)
Publisher : PT WIM Solusi Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54957/ijhs.v4i5.1088

Abstract

HPV merupakan kelompok virus penyebab kanker serviks. HPV16 menyebabkan 46-63% karsinoma sel skuamosa serviks. HPV16 terdiri dari 3 region siklus sel, yaitu early region (E), long control region (LCR), dan late region (L). Early region yang berasal dari protein E1, E2, E4, E5, E6, dan E7 berperan dalam ekspresi gen virus, replikasi virus, dan siklus hidup virus. Virus akan mengekspresikan protein E1 dan E2 kemudian terjadi delesi, dan sel yang terinfeksi akan berdiferensiasi dan mengekspresikan E6 dan E7. Ekspresi E6 dan E7 akan menurunkan ekspresi TLR9, IFN-1, dan supresi sitokin proinflamasi. Respons imun yang menurun menyebabkan sel yang terinfeksi berdiferensiasi menjadi sel kanker. Vaksinasi profilaksis digunakan sebagai pencegahan dan pengendalian infeksi virus HPV16, tetapi tidak dapat melindungi individu yang sudah terinfeksi dari perkembangan infeksi virus dan sel abnormal. Oleh karena itu, vaksinasi terapeutik diperlukan untuk imunoterapi kanker. Antigen HPV16 yang terdiri dari E2, E6, dan E7 diharapkan menjadi target yang baik. Antigen E2, E6, dan E7 bertujuan untuk mengaktifkan respons imun spesifik yang diperantarai sel untuk memfagositosis sel yang terinfeksi. Antigen diproses oleh sel dendritik dan kemudian disajikan kepada molekul MHC. MHC II akan merangsang respons sel T CD4+ terhadap protein yang akan membantu sel T CD8+ sitotoksik. Antigen disajikan oleh MHC I untuk dipresentasikan ke sel T CD8+ sitotoksik untuk mengeliminasi sel yang terinfeksi. Antigen E2, E6, dan E7 untuk imunoterapi guna mencegah perkembangan sel abnormal sehingga tidak berkembang menjadi kanker.
Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem Prasetyo, Dimas Seto; Herna, Herna; Mursinah, Mursinah; Ibrahim, Fera; Bela, Budiman
Jurnal Kefarmasian Indonesia VOLUME 12, NOMOR 1, FEBRUARI 2022
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v0i0.5008

Abstract

Lower respiratory tract, sepsis, or urinary tract infection caused by the multidrug resistance Pseudomonas aeruginosa is common in the hospital, especially in the ICU wards. The treatment against this bacteria requires combination of antibiotics with different mechanism of actions. In this study, several combinations of antibiotics were evaluated in vitro against carbapenem-resistant P. aeruginosa isolated from the ICU of Cipto Mangunkusumo Hospital. The combination of antibiotics tested were ceftazidime-amikacin, ceftazidime-ciprofloxacin, and ciprofloxacin-amikacin. Checkerboard assay to the combination of antibiotics was conducted to assess the in vitro synergistic activity. A total of 22 P. aeruginosa isolates were collected, 16 of them were resistant to ceftazidime, ciprofloxacin, amikacin, as well as carbapenem. The result revealed that the combination of ceftazidime and amikacin showed promising synergistic activity. Conversely, no synergitic activities were shown by the combination of ceftazidime-ciprofloxacin and ciprofloxacin-amikacin. The combination of ceftazidime-amikacin may has potential effect againsts carbapenem-resistant P. aeruginosa in vitro.
Mengatasi Tantangan Skrining HPV pada Perempuan: Sebuah Kajian Umum Bela, Budiman; Hartono, Soni; Pratiwi, Ekawati Betty; Cahyani, Hesti Pramesti; Widyaningtyas, Silvia Tri
Majalah Kedokteran Indonesia Vol 75 No 2 (2025): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.75.2-2025-1898

Abstract

Introduction: A major challenge in the success of HPV screening programs is achieving 70% coverage of women aged 30-69. This study conducted a survey to examine the factors influencing the willingness of woman in that age group to actively engage HPV screening program.Method: Socio-demographic data, knowledge levels, cervical cancer screening uptake, and willingness to participate in the government’s routine screening program were collected digitally using cross-sectional study. Factors associated with knowledge, participation, and willingness to engage program measured using logistic regression analysis.Result: Among the 87 eligible respondents, 96.6% had heard about cervical cancer mostly via internet, and 51% categorized as having low level knowledge. The percentage of participants willingness to participate in program was 67.82% below the percentage government target coverage. Factors correlated with willingness included: age group 36-40 (aOR = 1.865, 95% CI = 0.567-6.129) and 41-45 (aOR = 2.93, 95% CI = 0.762-11.272), monthly household expense (aOR = 1.682, 95% CI = 0.684-4.138), having relatives suffer cervical cancer (aOR = 2.764, 95% CI = 0.790-9.672), history of HPV vaccination (aOR = 1.187, 95% CI = 0.593-7.539).Conclusion: Respondent willingness to participate in HPV screening program remains to be improved. Various ways to increase participation in screening programs need to be developed to reach various populations of women.
THE CURRENT STRATEGIES, RECENT PROGRESS AND REMAINING CHALLENGES FOR DEVELOPING MRNA VIRAL VACCINE Irawan, Priscilla Felicia Apriliani; Bela, Budiman
Jurnal Bioteknologi & Biosains Indonesia (JBBI) Vol. 11 No. 1 (2024)
Publisher : BRIN - Badan Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/jbbi.2024.6422

Abstract

The mRNA expression system has revolutionised biotechnology, notably in viral mRNA vaccine development, cancer immunotherapy, and gene therapy. However, recent safety concerns regarding the COVID-19 mRNA vaccine have emerged, particularly regarding its rare adverse effects and its possible connection to cancer. This review explains several approaches used in developing viral mRNA vaccines, the past obstacles solved in generating the current COVID-19 mRNA vaccine, and finally the current advancements and ongoing challenges in the viral mRNA vaccine field. We particularly focus on strategies and methods to improve the safety and translation efficiency of the mRNA vaccine, such as enhancing the vaccine’s transfection specificity to targeted dendritic cells (DC) and using viral IRES or self-amplifying mRNA format to improve mRNA translation efficiency.
Pemilihan Peptida Immunogenik E6 Human Papiloma Virus 16 sebagai Kandidat Vaksin kuratif dengan menggunakan Next-Generation IEDB Tools Widyaningtyas, Silvia Tri; Pratiwi, Ekawati Betty; Bela, Budiman
InaBHS (Indonesian Journal of Biomedicine and Health Science) Vol 3 No 2 (2024): Indonesian Journal of Biomedicine and Health Science
Publisher : Fakultas Kedokteran UGJ Cirebon

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33603/inabhs.v3i2.10519

Abstract

ABSTRAK Kanker serviks atau kanker mulut rahim merupakan salah satu penyebab kematian tinggi sampai saat ini. Kanker ini dikaitkan dengan infeksi Human Pappiloma virus (HPV). Vaksinasi merupakan salah satu metode pencegahan yang cukup efektif untuk mencegah kanker serviks. Vaksin yang beredar saat ini efektif untuk mencegah infeksi HPV, namun kurang efektif jika diberikan pada orang yang telah terinfeksi. Hal tersebut dikaitkan dengan jalur kekebalan tubuh yang diinduksi oleh vaksin tersebut. Dalam penelitian ini dirancang antigen HPV 16 yang dapat digunakan dalam pengembangan vaksin terapetik yang ditujukan untuk meningkatkan respon kekebalan seluler yand secara spesifik dapat menghancurkan sel kanker servik. Pemilihan dan karakterisasi antigen dilakukan dengan menerapkan Bioinformatika. Parameter yang dinilai antara lain kemampuan antigen diproses dan dipresentasikan oleh sel tubuh pada sel kekebalan tubuh yang bertanggung jawab pada eliminasi sel kanker, yaitu sel CD8. Hasil studi menunjukkan diperoleh epitop CD8 yang dikenali oleh beberapa jenis HLA. Bioinformatika dapat digunakan untuk mencari epitop.
THE CURRENT STRATEGIES, RECENT PROGRESS AND REMAINING CHALLENGES FOR DEVELOPING MRNA VIRAL VACCINE Irawan, Priscilla Felicia Apriliani; Bela, Budiman
Jurnal Bioteknologi & Biosains Indonesia (JBBI) Vol. 11 No. 1 (2024)
Publisher : BRIN - Badan Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55981/jbbi.2024.6422

Abstract

The mRNA expression system has revolutionised biotechnology, notably in viral mRNA vaccine development, cancer immunotherapy, and gene therapy. However, recent safety concerns regarding the COVID-19 mRNA vaccine have emerged, particularly regarding its rare adverse effects and its possible connection to cancer. This review explains several approaches used in developing viral mRNA vaccines, the past obstacles solved in generating the current COVID-19 mRNA vaccine, and finally the current advancements and ongoing challenges in the viral mRNA vaccine field. We particularly focus on strategies and methods to improve the safety and translation efficiency of the mRNA vaccine, such as enhancing the vaccine’s transfection specificity to targeted dendritic cells (DC) and using viral IRES or self-amplifying mRNA format to improve mRNA translation efficiency.
Co-Authors Ade P.R. Simaremare Andi Yasmon Andrijono Andrijono Anggraini Alam Anis Anis Ardiana Kusumaningrum Armi Susandi Aroem Naroeni Aroem Naroeni Ascobat, Purwantyastuti ASRI SULFIANTI Beti Ernawati Dewi Cahyani, Hesti Pramesti Christina, Diana Cintera Rahmagiarti Diah Iskandriati Dian Amirulloh Dimas Seto Prasetyo Dondin Sajuthi Elisna Syahruddin Evy Yunihastuti FERA IBIRAHIM Fera Ibrahim Firdaus Sirait Ganjar Noviar Gede Eko Darmono Geraldine, Vanessa Hanifi, Muhammad Hartiyowidi Yuliawuri Hartono, Soni Herna Herna Herna, Herna Hertanto, Robby Ibnu Agus Ariyanto Iin Maemunah Ingrid S. Surono Irawan, Priscilla Felicia Apriliani Jeanne Adiwinata Pawitan Jeanne Elvia Christian Kamila, Etri Dian Ketut Tuti Parwati Lili Indrawati Maria Lina R. Maria Lina Rosilawati Melinda Remelia Muhayya, Syarifah Raisha Murdani Abdullah Mursinah Mursinah Mursinah Mursinah Ni Ken Ritchie Ni Nengah Dwi Fatmawati Nia Kurniati Nuzli Fahdia Mazfufah Pamungkas, Joko Pauline Phoebe Halim Pramita Gayatri Pratiwi, Ekawati Betty Radiana Dhewayani Antarianto SAHLAN, MUHAMAD Sari, Siska Yuliana Satyapertiwi, Dwiantari Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Triwidyaningtyas Sofy Meilany Subangkit Subangkit Subiantistha, Tanaya Sugiarta, Gede Yuda SUWIJIYO PRAMONO Utami, Mardhah Sastri VIVI SETIAWATY Widianingtyas, Silvia Widyaningtyas, Silvia Tri Wiseso, Anggoro Yohda, Masafumi YULIANTY MUHAYAR Yuliar Budi Hartanto Yusmaniar Yusmaniar Yuyun SM Soedarmono Yuyun Soedarmono Zakiudin Munasir